Department of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, 07103, NJ, USA; Department of Human Anatomy, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 45001, Henan, China; Neuroscience Research Institute, College of Basic Medicine, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Department of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, 07103, NJ, USA.
Neuropharmacology. 2018 Oct;141:238-248. doi: 10.1016/j.neuropharm.2018.09.003. Epub 2018 Sep 5.
Hemorrhages occurring within the thalamus lead to a pain syndrome. Clinical treatment of thalamic pain is ineffective, at least in part, due to the elusive mechanisms that underlie the induction and maintenance of thalamic pain. The present study investigated the possible contribution of a protein-protein interaction between postsynaptic density protein 95 (PSD-95) and neuronal nitric oxide synthase (nNOS) to thalamic pain in mice. Thalamic hemorrhage was induced by microinjection of type IV collagenase into unilateral ventral posterior medial/lateral nuclei of the thalamus. Pain hypersensitivities, including mechanical allodynia, heat hyperalgesia, and cold allodynia, appeared at day 1 post-microinjection, reached a peak 5-7 days post-microinjection, and persisted for at least 28 days post-microinjection on the contralateral side. Systemic pre-treatment (but not post-treatment) of ZL006, a small molecule that disrupts PSD-95-nNOS interaction, alleviated these pain hypersensitivities. This effect is dose-dependent. Mechanistically, ZL006 blocked the hemorrhage-induced increase of binding of PSD-95 with nNOS and membrane translocation of nNOS in thalamic neurons. Our findings suggest that the protein-protein interaction between PSD-95 and nNOS in the thalamus plays a significant role in the induction of thalamic pain. This interaction may be a promising therapeutic target in the clinical management of hemorrhage-induced thalamic pain.
丘脑内出血会导致疼痛综合征。临床治疗丘脑疼痛效果不佳,至少部分原因是诱导和维持丘脑疼痛的机制难以捉摸。本研究探讨了突触后密度蛋白 95(PSD-95)和神经元型一氧化氮合酶(nNOS)之间的蛋白-蛋白相互作用对小鼠丘脑疼痛的可能贡献。通过向丘脑腹后内侧/外侧核单侧微注射 IV 型胶原酶诱导丘脑内出血。疼痛过敏反应,包括机械性痛觉过敏、热痛觉过敏和冷痛觉过敏,在微注射后第 1 天出现,在微注射后第 5-7 天达到高峰,并在微注射后至少 28 天持续存在于对侧。ZL006(一种破坏 PSD-95-nNOS 相互作用的小分子)的全身预处理(而非后处理)缓解了这些疼痛过敏反应。这种效果是剂量依赖性的。从机制上讲,ZL006 阻断了出血引起的 PSD-95 与 nNOS 结合增加以及 nNOS 在丘脑神经元中的膜易位。我们的研究结果表明,丘脑内 PSD-95 和 nNOS 之间的蛋白-蛋白相互作用在丘脑疼痛的诱导中起重要作用。这种相互作用可能是治疗出血性丘脑疼痛的有前途的治疗靶点。